Xenon Pharmaceuticals Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Dawn Svoronos

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Dawn Svoronos”): 82,475,281 for, 4,517,221 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2027 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 88 asset managers below reported 34,217,715 for, 697,649 against.

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Elizabeth Garofalo

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Elizabeth Garofalo”): 84,808,573 for, 2,183,929 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2027 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 88 asset managers below reported 34,726,341 for, 189,023 against.

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gary Patou

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Gary Patou”): 86,114,511 for, 877,991 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2027 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 88 asset managers below reported 34,788,338 for, 127,026 against.

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gillian Cannon

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Gillian Cannon”): 84,844,120 for, 2,148,382 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2027 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 88 asset managers below reported 34,726,341 for, 189,023 against.

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Ian Mortimer

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Ian Mortimer”): 86,524,582 for, 467,920 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2027 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 88 asset managers below reported 34,888,487 for, 26,877 against.

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Justin Gover

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Justin Gover”): 86,290,281 for, 702,221 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2027 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 88 asset managers below reported 34,888,487 for, 26,877 against.

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Patrick Machado

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Patrick Machado”): 86,603,916 for, 388,586 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2027 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 88 asset managers below reported 34,888,487 for, 26,877 against.

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Steven Gannon

Xenon Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Steven Gannon”): 86,149,107 for, 843,395 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2027 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 88 asset managers below reported 34,888,487 for, 26,877 against.

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

Description as filed by funds: To approve the Corporation's 2026 Equity Incentive Plan;

Xenon Pharmaceuticals Inc.’s own tally for this item (“4. 2026 Equity Incentive Plan”): 58,579,810 for, 27,570,443 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's 2026 Equity Incentive Plan was approved as follows:”
Support: 68% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 91 asset managers below reported 28,156,126 for, 7,101,763 against, 3,000 abstained.

Showing the 25 largest of 91 asset managers. See all 91 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Corporation's named executive officers;

Xenon Pharmaceuticals Inc.’s own tally for this item (“2. Advisory Vote on Compensation of Named Executive Officers ("Say-on-Pay")”): 82,156,320 for, 4,769,025 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The compensation of the Company's named executive officers, on an advisory basis, was approved as follows:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 88 managers: 34,357,280 for, 538,293 against, 26,877 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 248 managers: 79,162,162 for, 4,245,991 against, 4 abstained, 1,335 not voted, 18,687 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the frequency of future shareholder advisory votes to approve the compensation of the Corporation's named executive officers;

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 86 managers: 147,413 for, 26,877 abstained, 34,740,388 1 year, 1 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 244 managers: 1,946,816 for, 435 against, 1,434 not voted, 81,061,247 1 year, 53,653 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To appoint PricewaterhouseCoopers LLP as the Corporation's auditor to hold office until the next annual meeting of the Corporation;

The 87 asset managers below reported 34,887,810 for, 26,877 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

Description as filed by funds: To authorize the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the auditors of the Corporation; and

Xenon Pharmaceuticals Inc.’s own tally for this item (“6. Remuneration of Auditor”): 90,370,029 for, 2,369 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The authority of the audit committee of the Board to set the remuneration of the auditor for the ensuing year was approved as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 34,887,810 for, 26,877 abstained.

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.